Strategic partnership SCBT has recently engaged with ERS Genomics on a nonexclusive CRISPR/Cas9 patent license, indicating openness to collaboration and external technology licensing opportunities.

Growth potential With a revenue range of 50M to 100M and a headcount under 200, SCBT represents a mid‑market biotech with room for scalable supplier, service, and platform solutions without enterprise‑level procurement complexity.

Technology footprint Existing tech stack includes Node.js, ATG Web Commerce, jQuery, and analytics tools like MouseFlow, suggesting opportunities for modern software, e-commerce optimization, customer experience enhancements, and data analytics partnerships.

Talent pipeline A Dallas headquarters and collaborative culture indicate potential for local BDR and field‑based outreach, as well as partnerships around recruitment solutions, training services, and workforce development programs.

Market positioning SCBT operates in biotechnology research with notable collaborators; selling points for expansion include compliance, licensing advisory, CRO/DMO services, and consumables or reagents that align with CRISPR, genomic research, and lab automation.